Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SENFIB

Financiado

Novel senolytic drugs for the treatment of lung and kidney fibrosis

SENFIB aims to deliver new drugs for the treatment of fibrotic diseases. Nearly one quarter of the global population will be over the age of 65 by 2050. Populations over 65 suffer from multiple degenerative diseases including tis... ver más

31/10/2022

FUNDACIO INSTITUT...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

FUNDACIO INSTITUT DE RECERCA BIOMEDICA IRB BA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 23M€

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-10-31

ERC-2020-POC: Call for proposals for ERC Proof of...

I+D

Cerrada hace 4 años

0% 100% 100%

2 Participantes

FUNDACIO INSTITUT DE RECERCA...

150.00K€ | Lider

VISCOFAN

664.20K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2012-39947-C02-02 MIRNA NANODELIVERY AND RENAL FIBROSIS 105K€ Cerrado

CNS2023-143944 Materiales para biomedicina 200K€ Cerrado

BES-2016-076757 ESTUDIO DEL PAPEL DE CORTISTATINA EN FIBROSIS: POTENCIAL APL... 93K€ Cerrado

BES-2015-071359 CARACTERIZACION DE DIANAS EPIGENETICAS CLAVE PARA EL DESARRO... 93K€ Cerrado

SAF2008-01767 ACIDOS RETINOICOS Y 15-DESOXI-DELTA12,14-PROSTAGLANDINA J2 C... 121K€ Cerrado

SAF2017-89908-R ENTENDIENDO EL PAPEL DE LAS CELULAS MADRE DE PULMON EN LA RE... 171K€ Cerrado

Duración del proyecto: 22 meses Fecha Inicio: 2020-12-14
Fecha Fin: 2022-10-31

Líder del proyecto

FUNDACIO INSTITUT DE RECERCA BIOMEDICA IRB BA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 23M€

Presupuesto del proyecto 150K€

Descripción del proyecto SENFIB aims to deliver new drugs for the treatment of fibrotic diseases. Nearly one quarter of the global population will be over the age of 65 by 2050. Populations over 65 suffer from multiple degenerative diseases including tissue fibrosis, estimated to account for upwards of 45% of all-cause mortality. Animal models have demonstrated that senescent cells are causative in many fibrotic diseases including lung (i.e. idiopathic pulmonary fibrosis, IPF), and chronic kidney disease (CKD). Senescent cells have experienced damage or stress and have permanently exited the cell cycle, yet remain viable and long-lived, generating a persistent, sterile inflammation. Selective elimination of senescent cells in animal models of IPF, CKD, and aging demonstrated improved organ function and viability. Senolytics, molecules that induce preferential killing of senescent cells while leaving healthy cells intact, have emerged as a promising approach for tackling age-associated diseases; this was named one of the 10 Breakthrough Technologies of 2020 by the MIT Technology Review. Thus far, few senolytics have been identified; their mode of action is often unknown, some present serious toxicities, and none has yet been demonstrated to have therapeutic activity in clinical trials. We propose to launch a drug discovery program based on a prioritized novel genetic target for senolysis, which we have already validated as senolytic using a tool compound in an in vivo model of IPF. We will deliver a lead series of molecules with IPR that meet all typical drug requirements plus in vivo Proof-of-Concept data in different mouse models of IPF and CKD. The ultimate goal of this project is to develop candidates for translation into clinical use to ameliorate fibrotic diseases via the selective elimination of senescent cells.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores